IL-15-based fusions to IL-7 and IL-21

US12410224B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12410224-B2
Application numberUS-202318472053-A
CountryUS
Kind codeB2
Filing dateSep 21, 2023
Priority dateAug 28, 2017
Publication dateSep 9, 2025
Grant dateSep 9, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.

First claim

Opening claim text (preview).

What is claimed is: 1. A soluble fusion protein complex comprising: a first fusion protein comprising interleukin-21 (IL-21) (SEQ ID NO: 6) and interleukin-15 receptor alpha sushi-binding domain/Fc (IL-15RαSu/Fc) (SEQ ID NO:8); and a second fusion protein comprising interleukin-7 (IL-7) (SEQ ID NO:10) and an IL-15 variant comprising an N72D mutation (IL-15N72D) (SEQ ID NO:12) or human wild-type IL-15, wherein the first and second fusion proteins are non-covalently linked to form the soluble fusion protein complex. 2. The soluble fusion protein complex of claim 1 , wherein the IL-21 is attached to the N-terminus of the IL-15RαSu/Fc. 3. The soluble fusion protein complex of claim 1 , wherein the IL-21 is attached to the C-terminus of the IL-15RαSu/Fc. 4. The soluble fusion protein complex of claim 2 , wherein the IL-7 is attached to the N-terminus of the IL-15N72D or the human wild-type IL 15. 5. The soluble fusion protein complex of claim 2 , wherein the IL-7 is attached to the C-terminus of the IL-15N72D or the human wild-type IL-15. 6. The soluble fusion protein complex of claim 3 , wherein the IL-7 is attached to the N-terminus of the IL-15N72D or the human wild-type IL-15. 7. The soluble fusion protein complex of claim 3 , wherein the IL-7 is attached to the C-terminus of the IL-15N72D or the human wild-type IL-15. 8. The soluble fusion protein complex of claim 1 , wherein the soluble fusion protein complex is covalently linked to a second soluble fusion protein complex by a disulfide bond linking the Fc domain of the first soluble fusion protein complex to an Fc domain of the second soluble fusion protein complex, wherein the second soluble fusion protein complex is identical to the first soluble fusion protein complex.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12410224B2 cover?
The invention features multi-specific fusion protein complexes with one domain comprising IL-15 or a functional variant and a binding domain specific to IL-7 or IL-21.
Who is the assignee on this patent?
Altor Bioscience Llc
What technology area does this patent fall under?
Primary CPC classification C07K14/7155. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).